AN2 Therapeutics Files Q1 2025 10-Q
Ticker: ANTX · Form: 10-Q · Filed: May 13, 2025 · CIK: 1880438
Sentiment: neutral
Topics: 10-Q, quarterly-report, pharmaceuticals
TL;DR
AN2 Therapeutics Q1 2025 10-Q filed. Focus on pharma R&D.
AI Summary
AN2 Therapeutics, Inc. filed its 10-Q for the period ending March 31, 2025. The company's primary focus remains on its pharmaceutical preparations business. Key financial data and operational details for the first quarter of 2025 are presented in this filing.
Why It Matters
This filing provides investors with an update on AN2 Therapeutics' financial health and operational progress during the first quarter of 2025.
Risk Assessment
Risk Level: medium — As a pharmaceutical company, AN2 Therapeutics is subject to inherent risks related to drug development, regulatory approvals, and market competition.
Key Numbers
- 20250331 — Reporting Period End Date (Indicates the end of the fiscal quarter for which financial information is reported.)
- 20250513 — Filing Date (The date the 10-Q report was officially submitted to the SEC.)
Key Players & Entities
- AN2 Therapeutics, Inc. (company) — Filer of the 10-Q
- 20250331 (date) — End of the reporting period
- 20250513 (date) — Filing date
- 0000950170-25-070358 (accession_number) — Unique identifier for the filing
- Menlo Park, CA (location) — Company's business and mailing address
FAQ
What is the primary business of AN2 Therapeutics, Inc.?
AN2 Therapeutics, Inc. is primarily involved in Pharmaceutical Preparations, as indicated by its SIC code [2834].
For what period is this 10-Q filing?
This 10-Q filing is for the period ending March 31, 2025.
When was this 10-Q filed with the SEC?
This 10-Q was filed on May 13, 2025.
What is the company's stated address?
The company's business and mailing address is 1800 El Camino Real, Suite D, Menlo Park, CA 94027.
What is the SEC file number for AN2 Therapeutics?
The SEC file number for AN2 Therapeutics is 001-41331.
Filing Details
This Form 10-Q (Form 10-Q) was filed with the SEC on May 13, 2025 regarding AN2 Therapeutics, Inc. (ANTX).